陳志毅 教授

 
專長:
  1. 胸腔外科
  2. 胸腔腫瘤外科
  3. 肺癌治療
  4. 胸腔重症
 
現職:
  • 中國醫藥大學附設醫院癌症中心院長
  • 中國醫藥大學健康照護學院二年制呼吸治療學系教授
 
學歷:
  • 台北醫學大學醫學系醫學士
 
電話: 04-22052121 #1921
傳真: 04-22070298
電子信箱: micc@mail.cmuh.org.tw
 
簡介:
    陳志毅教授目前擔任中國醫藥大學暨附設醫院癌症中心院長,曾任職台北榮總外科、美國明尼蘇達大學醫學中心臨床研究員、台中榮民總醫院胸腔外科主任。歷年來致力於胸腔腫瘤外科醫療,整合癌症之臨床及基礎研究,並且與台灣各大學及醫學中心合作,組織肺癌研究團隊。陳教授三十年來發表超過200篇SCI論文,近四年更發表18篇超過IF>5文章,其中與Dr. Garzdar共同發現台灣女性肺癌高EGFR之突變特性 (JNCI 2005),對台灣肺癌個人化治療助益極大。由於陳教授對於早期肺癌致病機轉的研究,有助於台灣肺癌之早期預防、早期診斷、治療政策推動及醫師培育。而陳院長所領導醫療體系癌症中心,四年來臨床服務及基礎研究皆呈倍數成長,更是中國附醫執行衛生署「癌症卓越研究中心計畫」之計畫主持人,實屬傑出的臨床科學家及領導者。
 
代表性著作:
  1. Yeh KT, Wu YH, Lee MC, Wang L, Li CT, Chen CY, and Lee H. XPC mRNA Level May Predict Relapse in Never-smokers with Non-Small Cell Lung Cancers. Ann Surg Oncol. 2012 Mar;19(3):734-42.
  2. Soh KS, Chen PR, Fang HY, and Chen CY. Pulmonary sequestration after resection of contralateral congenital pulmonary sequestration. Eur J Cardiothorac Surg. 2012 Mar 1. (Correspondence to: Chih-Yi Chen)
  3. Hosgood HD 3rd, Wang WC, Hong YC, Wang JC, Chen K, Chang IS, Chen CJ, Lu D, Yin Z, Wu C, Zheng W, Qian B, Park JY, Kim YH, Chatterjee N, Chen Y, Chang GC, Hsiao CF, Yeager M, Tsai YH, Wei H, Kim YT, Wu W, Zhao Z, Chow WH, Zhu X, Lo YL, Sung SW, Chen KY, Yuenger J, Kim JH, Huang L, Chen YH, Gao YT, Kim JH, Huang MS, Jung TH, Caporaso N, Zhao X, Huan Z, Yu D, Kim CH, Su WC, Shu XO, Kim IS, Bassig B, Chen YM, Cha SI, Tan W, Chen H, Yang TY, Sung JS, Wang CL, Li X, Park KH, Yu CJ, Ryu JS, Xiang Y, Hutchinson A, Kim JS, Cai Q, Landi MT, Lee KM, Hung JY, Park JY, Tucker M, Lin CC, Ren Y, Perng RP, Chen CY, Jin L, Chen KC, Li YJ, Chiu YF, Tsai FY, Yang PC, Fraumeni JF Jr, Seow A, Lin D, Zhou B, Chanock S, Hsiung CA, Rothman N, and Lan Q. Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia.Hum Genet. 2012 Feb 25.
  4. Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, Lin CH, Lee H, and Cheng YW. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.Anticancer Res. 2011 Oct;31(10):3475-81.
  5. Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, Chen HW, Chen CY, Yu CJ, Shih JY, Chang YL, Cheng CL, Hsu CP, Hsia JY, Lin CY, Wu G, Liu CH, Wang CD, Yang KC, Chen YW, Lai YL, Hsu CC, Lin TC, Yang TY, Chen KC, Hsu KH, Chen JJ, Chang GC, Li KC, and Yang PC. Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With EGFR-Activating Mutations. J Clin Oncol. 2011 Aug 1.
  6. Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang J, Chen CY, and Lee H. A Polymorphic -844T/C in FasL Promoter Predicts Survival and Relapse in Non-Small Cell Lung Cancer. Clin Cancer Res. 2011 Aug 1.
  7. Fang HY, Chen CY, Chiou SH, Wang YT, Lin TY, Chang HW, Chiang IP, Lan KJ, and Chow KC. Overexpression of optic atrophy 1 protein increases cisplatin resistance via inactivation of caspase-dependent apoptosis in lung adenocarcinoma cells. Hum Pathol. 2011 Jul 26.
  8. Chen SC, Shih CM, Tseng GC, Cheng WE, Chiou J, Hsiao M, Kuo ML, Su JL, and Chen CY. Vascular endothelial growth factor C as a predictor of early recurrence and poor prognosis of resected stage I non-small cell lung cancer.Ann Acad Med Singapore. 2011 Jul;40(7):319-6. (Correspondence to: Chih-Yi Chen)
  9. Fang HY, Chen CY, Hung MF, Hsiao YT, Chiang TC, Lin TY, Chang HW, Chow KC, and Ko WJ. Caspase-14 is an anti-apoptotic protein targeting apoptosis-inducing factor in lung adenocarcinomas. Oncol Rep. 2011 Apr 29.
  10. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, and Lee H. Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway is associated with poor relapse free survival in Early-stage Human Papillomavirus - associated Lung cancer.Clin Cancer Res. 2011 May;25(5):1243-51.
  11. Chen CY, Fang HY, Chiou SH, Yi SE, Huang CY, Chiang SF, Chang HW, Lin TY, Chiang IP, and Chow KC. Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci. 2011 May 7.
  12. Chen PR, Chen CK, Lin YS, Huang HC, Tsai JS, Chen CY, and Fang HY. Single-incision thoracoscopic surgery for primary spontaneous pneumothorax. Journal of Cardiothoracic Surgery 2011 April;21:6(1):58.
  13. Hsu KH, Chen KC, Yang TY, Yeh YC, Chou TY, Chen HY, Tsai CR, Chen CY, Hsu CP, Hsia JY, Chuang CY, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Hsiung CA, Chang GC, Chen CJ, and Yang PC. Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns. J Thorac Oncol. 2011 Apr 20.
  14. Lai TC, Chow KC, Fang HY, Cho HC, Chen CY, Lin TY, Chiang IP, and Ho SP. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.Oncol Rep. 2011 Feb 14.
  15. Yang SY, Yang TY, Chen KC, Li YJ, Hsu KH, Tsai CR, Chen CY, Hsu CP, Hsia JY, Chuang CY, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Hsiung CA, Shen CY, Chang GC, Yang PC, and Chen CJ. EGFR L858R Mutation and Polymorphisms of Genes related to Estrogen Biosynthesis and Metabolism in Never-smoking Female Lung Adenocarcinoma Patients. Clin Cancer Res. 2011 Feb 7.
  16. Chen SC, Liu JC, Tseng GC, and Chen CY. Rare presentation of pulmonary cryptococcosis as a calcified nodule. Intern Med. 2011,50(2):169-70.
  17. Wu HH, Cheng YW, Chang JT, Wu TC, Liu WS, Chen CY, and Lee H. Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kB activation. Oncogene 2010,29:4330–40. (Correspondence to: Chih-Yi Chen and Huei Lee)
  18. Wu DW, Cheng YW, Wang J, Chen CY, and Lee H. Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting. Cancer Res. 2010 Dec 15;70(24):10392-10401.
  19. Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, Sung FC, and Chen CY. Increased Lung Cancer Risk among Patients with Pulmonary Tuberculosis: A Population Cohort Study. J Thorac Oncol. 2010 Dec 8.(Correspondence to: Chih-Yi Chen)
  20. Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG, and Lee H. cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18–Infected Lung Cancer. Clin Cancer Res. 2010 Nov;16(21):5200-10.
  21. Wu YH, Wu TC, Liao JW, Yeh KT, Chen CY, and Lee H. P53 Dysfunction by Xeroderma Pigmentosum Group C Defects Enhances Lung Adenocarcinoma Metastasis VIA Increased MMP1 Expression. Cancer Res. 2010 Nov 5.
  22. Li YH, Shieh SH, and Chen CY. The influence of Health Behaviors on Survival in Lung Cancer Patients in Taiwan. Jpn J Clin Oncol. 2010 Oct.
  23. Li YH, Shieh SH, and Chen CY. The influence of Health Behaviors on Survival in Lung Cancer Patients in Taiwan. Jpn J Clin Oncol. 2010 Oct.
  24. Lai TC, Chow KC, Lin TY, Chiang IP, Fang HY, Chen CY, and Ho SP. Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas. Oncol Rep. 2010 Aug;24(2):321-328.
  25. Hsiung CA, Lan Q, Hong YC, Chen CJ, Hosgood HD, Chang IS, Chatterjee N, Brennan P, Wu C, Zheng W, Chang GC, Wu T, Park JY, Hsiao CF, Kim YH, Shen H, Seow A, Yeager M, Tsai YH, Kim YT, Chow WH, Guo H, Wang WC, Sung SW, Hu Z, Chen KY, Kim JH, Chen Y, Huang L, Lee KM, Lo YL, Gao YT, Kim JH, Liu L, Huang MS, Jung TH, Jin G, Caporaso N, Yu D, Kim CH, Su WC, Shu XO, Xu P, Kim IS, Chen YM, Ma H, Shen M, Cha SI, Tan W, Chang CH, Sung JS, Zhang M, Yang TY, Park KH, Yuenger J, Wang CL, Ryu JS, Xiang Y, Deng Q, Hutchinson A, Kim JS, Cai Q, Landi MT, Yu CJ, Park JY, Tucker M, Hung JY, Lin CC, Perng RP, Boffetta P, Chen CY, Chen KC, Yang SY, Hu CY, Chang CK, Fraumeni JF Jr, Chanock S, Yang PC, Rothman N, and Lin D. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet. 2010 Aug 5;6(8):1-8.
  26. Chen CK, Jan CI, Tsai JS, Huang HC, Chen PR, Lin YS, Chen CY, and Fang HY. Inflammatory myofibroblastic tumor of the lung: a case report. J Cardiothorac Surg. 2010 Jul 20;5(1):55.
  27. Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, Lu YY, Tang YA, Yang YC, Yang PC, and Wang YC. Dysregulation of p53/Sp1 Control Leads to DNA Methyltransferase-1 Overexpression in Lung Cancer. Cancer Res. 2010 Jun;22:5807-17.
  28. Fang HY, Chang CL, Hsu SH, Huang CY, Chiang SF, Chiou SH, Huang CH, Hsiao YT, Lin TY, Chiang IP, Hsu WH, Sugano S, Chen CY, Lin CY, Ko WJ, and Chow KC. ATPase family AAA domain-containing 3A is a novel anti-apoptotic factor in lung adenocarcinoma cells. J Cell Sci. 2010 Apr;123(Pt 7):1171-80.
  29. Chien CR, Yang ST, Chen CY, Fang HY, Tu CY, Tseng GC, Yu YH, Chen HJ, Ho CT, Hsieh CY, Chen HN, Chen PR, Liu JC, Wang YC, Wu HH, and Hsia TC. Impact of the New Lung Cancer Staging System for a Predominantly Advanced-Disease Patient Population. J Thorac Oncol. 2010 Mar;5(3):340-3.
  30. Liu JF, Fong YC, Chang CS, Huang CY, Chen HT, Yang WH, Hsu CJ, Jeng LB, Chen CY, and Tang CH. Cyclooxygenase-2 enhances α2β1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer.2010 Feb 23;9:43.
  31. Lin RK, Hsieh YS, Lin P, Hus HS, Chen CY, Lee CF, and Wang TC. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients.J Clin Invest.2010 Feb;120(2):521-32.
  32. Shih CM, Chen CY, Lee IH, Kao WT and Wang YC. A Polymorphism in the hMLH1 gene (-93G –>A) associated with lung cancer susceptibility and prognosis. Int J Mol Med. 2010 Jan;25(1):165-70.
  33. Chien WP, Wong RH, Cheng YW, Chen CY, and Lee H. Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Transcriptio Patients with Wild-Type p53 Tumors. Ann Surg Oncol. 2009 Nov.
  34. Chien CR, Lin CY, and Chen CY. Re: Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and Age. J Natl Cancer Inst. 2009 Sep 1.
  35. Tseng RC, Hsieh FJ, Shih CM, Hsu HS, Chen CY, and Wang YC. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. Cancer 2009 Jul 1;115(13):2939-48.
  36. Chien WP, Wong RH, Wu TC, Cheng YW, Chen CY and Lee H. Protenial Increase in the Prognostic Value of p53 mutation by pro72 Allele in Stage I Non-Small-Cell Lung Cancer. Ann Surg Oncol. 2009 Jul;16(7):1918-24.
  37. Lai JC, Wu JY, Cheng YW, Yeh KT, Wu TC, Chen CY and Lee H. O6 -Methylquanine-DNA Methyltransferase Hypermethylation modulated by 17β-Estrodiol in Lung Cancer cells. Anticancer Res. 2009 Jul;29(7):2535-40.
  38. Hsieh WC, Cheng YW, Lin CJ, Chou MC, Chen CY, and Lee H. Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer.Jpn J Clin Oncol. 2009 Feb;39(2):81-5.
  39. Fong YC, Liu SCh, Huang CY, Li TM, Hsu SF, Kao ST, Tsai FJ, Chen WC, Chen CY, and Tang CH. Osteopontin Increases Lung Cancer Cells Migration via Activation of the αvß3 Iintegrin/FAK/Akt and NF-κB-Dependent Pathway. Lung Cancer. 2009 Jun;64(3):263-70.
  40. Hsu NY, Cheng YW, Chan IP, Ho HC, Chen CY, Hsu CP, Lin MH and Chou MC. Association Between Expression of Human Peapillomavirus 16/18 E6 Oncoprotein and Survival in Patients with Stage I Non-Small Cell Lung. Cancer Oncol Rep. 2009 Jan;21(1):81-7.
  41. Hsu NY, and Chen CY. The Clinical Significance of Reoperation for Lung Cancer .J. Chinese Oncol Soc. 2008 Dec;24(6):356-361.
  42. Cheng YW, Wu TC, Chen CY, Chou MC, Ko JL, and Lee H. Human Telomerase Reverse Transcriptase Activated by E6 Oncoprotein Is Required for Human Papillomavirus-16/18-Infected Lung Tumorigenesis. Clin Cancer Res. 2008 Nov15;14(22):7173-9.
  43. Wu JY, Wang J, Lai JC, Cheng YW, Yeh KT, Wu TC, Chen CY, and Lee H. Association of O6-Methylguanine-DNA Methyltransferase(MGMT) Promoter Methylation with p53 Mutation Occurrence in Non-Small Cell Lung Cancer with Different Histology, Gender, and Smoking Status.Ann Surg Oncol. 2008 Nov;15(11):3272-7.
  44. Chien CR, Chen CY, and Liang JA. Re: Intensity-Modulated Radiation Therapy Dose Prescription, Recording, and Delivery: Patterns of Variability Among Institutions and Treatment Planning Systems.J Natl Cancer Inst. 2008 Sep 3;100(17):1264-5.
  45. Hsu NY, and Chen CY. Clinical Significance of Limited Resection in Lung Cancer surgrery. Chin J Lung Cancer. 2008 Aug;11(4):477-81.
  46. Lai JC, Cheng YW, Goan YG, Chang JT, Wu TC, Chen CY, and Lee H. Promoter Methylation of O6-Methylguanine-DNA -Methyltransferase in Lung Cancer Is Regulated by p53. DNA Repair (Amst). 2008 Aug;7(8):1352-63.
  47. Hsu NY, Yeh KT, Chiang IP, Pai LY, Chen CY, and Ho HC. Cortactin Overexpression in the Esophageal Squamous Cell Carcinoma and its Involvement in the Carcinogenesis. Disease of the esophagus 2008,21:402-8.
  48. Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY, and Chow KC. HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells.Am J Respir Cell Mol Biol. 2008 May;38(5):559-65.
  49. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJW, and Yang PC. MicroRNA Signature Predicts Survival and Relapse in Lung Cancer.Cancer Cell. 2008 Jan;13(1):48-57.
  50. Hsieh TC, Chen CY, Chiang YJ, Lai JH, and Hsu NY. The Potential Prognostic Role of Thallium-201 SPECT in Patients with Esophageal Cancer: Comparison with Pathological Finding. Ann Nucl Med Sci. 2007,20(3):121-7.
  51. Hsu HS, Chen TP, Wen CK, Hung CH, Chen CY, Chen JT, and Wang YC. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol. 2007 Dec;213(4):412-9.
  52. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, Chen CY, and Lee H. Human Papillomavirus 16/18 E6 Oncoprotein Is Expressed in Lung Cancer and Related with p53 Inactivation. Cancer Res. 2007 Nov 15;67(22):10686-93.
  53. Hsu NY, Chen CY, Hsu CP, Lin TY, Chou MC, Chiou SH, and Chow KC. Prognostic Significance of Expression of nm23-H1 and Focal Adhesion Kinase in Non-Small Cell Lung Cancer.Oncol Rep. 2007 Jul;18(1):81-5.
  54. Wu YH, Cheng YW, Chang JT, Wu TC, Chen CY, and Lee H. Reduced XPC Messenger RNA Level May Predict a Poor Outcome of Patients with Nonsmall Cell lung Cancer. Cancer 2007 Jul 1;110(1):215-23.
  55. Hsu WH, Yu YH, Tu C-Y, Hsu JY, Chen CY, Chen CL, and Kwan PC. Color Doppler US Pulmonary Artery Vessel Signal: A Sign for Predicting the Benign Lesions. Ultrasound Med Biol. 2007 Mar;33(3):379-88.
  56. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, and Wang YC. Alteration of DNA Methyltransferases Contributes to 5'CpG Methylation and Poor Prognosis in Lung Cancer. Lung Cancer. 2007 Feb;55(2):205-13.
  57. Cheng YW, Tsai HJ, Wu JY, Hsu Y-F, Chen CY, Hao NJ, and Lee H. A Possible Role for Dihydrodiol Dehydrogenase in the Formation of Benzo[a]Pyrene-DNA Adducts in Lung Cancer Cells and Tumor Tissues. Environ Mol Mutagen2007 Jan;48(1):14-21.
  58. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJW, and Yang PC. A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer. NEngl J Med. 2007 Jan 4;356(1):11-20.
  59. Perng RP, Chen CY, Chang GC, Hsia TC, Hsu NY, Tsai YH, Tsai CM, Yang CH, Chen YM, Yu CJ, Lee JJ, Hsu HS, Yu CT, Kao EL, and Chiu CH. Revisit of 1997 TNM Staging System--Survival Analysis of 1112 Lung Cancer Patients in Taiwan. Jpn. J. Clin. Oncol. 2007;37(1):9-15.